$PLPL Vice President Gives Online Proactive Investors Interview

In the interview, Mr. Cottrell-Duffield addressed recent sales of the company’s flagship product, Phytofare®, stating, “Sales have thus far been focused in Europe, where we have first-rate distributor representation, and in South Africa, where we have strong support for local companies. With our new distribution partner in AIDP, we also now have excellent representation in North America and Asia.” With respect to customer preferences, Mr. Cottrell-Duffield added, “Consumers are now beginning to understand the importance of bioavailability in their nutriceutical products. While other products may claim bioavailability, Phytofare® is the only catechin complex on the market that can support that claim with double-blind human clinical trials. This is a tremendous market advantage for Plandaí.”

Mr. Cottrell-Duffield was then questioned about the company’s research into medical cannabis applications, to which he responded, “Plandaí is not currently nor has it ever produced cannabis extracts or tested any cannabis extracts. The legal environment in the United States is currently such that, as a listed company, doing so would be problematic. We have received a license from the Uruguay government to produce a cannabis extract and conduct animal trials, but, as their cannabis legislation is so new, there is still no clear path for moving forward. As soon as possible, we plan to produce a cannabis extract and prove that we can make a non-psychoactive product that retains the medical benefits of cannabis without the associated ‘high.'”

The full video interview can be accessed online at https://www.proactiveinvestors.co.uk/or alternatively can be found on the following YouTube link:https://www.youtube.com/watch?v=jHvbc3v7Z1E.

For trade inquiries please email: info@phytofare.com

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit https://www.plandaibiotech.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC’s website located at https://www.sec.gov.